Article

Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine.

Max Planck Institute of Psychiatry, Munich, Germany.
Neuropsychopharmacology (Impact Factor: 7.83). 05/2006; 31(4):832-44. DOI: 10.1038/sj.npp.1300923
Source: PubMed

ABSTRACT The noradrenergic and specific serotoninergic antidepressant mirtazapine improves sleep, modulates hormone secretion including blunting of hypothalamic-pituitary-adrenocortical (HPA) activity, and may prompt increased appetite and weight gain. The simultaneous investigation of sleep electroencephalogram (EEG) and hormone secretion during antidepressive treatment helps to further elucidate these effects. We examined sleep EEG (for later conventional and quantitative analyses) and the nocturnal concentrations of cortisol, adrenocorticotropin (ACTH), growth hormone (GH), prolactin, melatonin and the key factors of energy balance, ghrelin, and leptin before and after 28 days of treatment of depressed patients (seven women, three men, mean age 39.9+/-4.2 years) with mirtazapine. In addition, a sleep EEG was recorded at day 2 and the dexamethasone-corticotropin-releasing hormone (DEX-CRH) test was performed to assess HPA activity at days -3 and 26. Psychometry and mirtazapine plasma concentrations were measured weekly. Already at day 2, sleep continuity was improved. This effect persisted at day 28, when slow-wave sleep, low-delta, theta and alpha activity, leptin and (0300-0700) melatonin increased, and cortisol and ghrelin decreased. ACTH and prolactin remained unchanged. The first two specimens of GH collected after the start of quantitative EEG analysis were reduced at day 28. The DEX-CRH test showed, at day 26, a blunting of the overshoot of ACTH and cortisol found at day -3. The Hamilton Depression score decreased from 32.1+/-7.3 to 15.5+/-6.7 between days -1 and 28. A weight gain of approximately 3 kg was observed. This unique profile of changes is compatible with the action of mirtazapine at 5-HT-2 receptors, at presynaptic adrenergic alpha 2 receptors, at the HPA system, and on ghrelin and leptin.

0 Bookmarks
 · 
243 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Confidence judgments are often severely distorted: People may feel underconfident when responding correctly or, conversely, overconfident in erred responses. Our aim here was to identify the timing of brain processes that lead to variations in objective performance and subjective judgments of confidence. We capitalized on the Partial Report Paradigm [Sperling, G. The information available in brief visual presentations. Psychological Monographs: General and Applied, 74, 1, 1960], which allowed us to separate experimentally the moment of encoding of information from that of its retrieval [Zylberberg, A., Dehaene, S., Mindlin, G. B., & Sigman, M. Neurophysiological bases of exponential sensory decay and top-down memory retrieval: A model. Frontiers in Computational Neuroscience, 3, 2009]. We observed that the level of subjective confidence is indexed by two very specific evoked potential at latencies of about 400 and 600 msec during the retrieval stage and by a stationary measure of intensity of the alpha band during the encoding period. When factoring out the effect of confidence, objective performance shows a weak effect during the encoding and retrieval periods. These results have relevant implications for theories of decision-making and confidence, suggesting that confidence is not constructed online as evidence is accumulated toward a decision. Instead, confidence attributions are more consistent with a retrospective mechanism that monitors the entire decision process.
    Journal of Cognitive Neuroscience 11/2014; DOI:10.1162/jocn_a_00759 · 4.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ScienceDirect j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / p s y n e u e n Summary Ghrelin is a 28-amino-acid peptide hormone, first described in 1999 and broadly expressed in the organism. As the only known orexigenic hormone secreted in the periphery, it increases hunger and appetite, promoting food intake. Ghrelin has also been shown to be involved in various physiological processes being regulated in the central nervous system such as sleep, mood, memory and reward. Accordingly, it has been implicated in a series of psychiatric disorders, making it subject of increasing investigation, with knowledge rapidly accumulating. This review aims at providing a concise yet comprehensive overview of the role of ghrelin in psychiatric disorders. Ghrelin was consistently shown to exert neuroprotective and memory-enhancing effects and alleviated psychopathology in animal models of dementia. Few human studies show a disruption of the ghrelin system in dementia. It was also shown to play a crucial role in the pathophysiology of addictive disorders, promoting drug reward, enhancing drug seeking behavior and increasing craving in both animals and humans. Ghrelin's exact role in depression and anxiety is still being debated, as it was shown to both promote and alleviate depressive and anxiety-behavior in animal studies, with an overweight of evidence suggesting antidepressant effects. Not surprisingly, the ghrelin system is also implicated in eating disorders, however its exact role remains to be elucidated. Its widespread involvement has made the ghrelin system a promising target for future therapies, with encouraging findings in recent literature.
    Psychoneuroendocrinology 11/2014; 52:176-194. DOI:10.1016/j.psyneuen.2014.11.013 · 5.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: During nocturnal sleep, blood pressure (BP) "dips" compared to diurnal BP, reducing stress on the cardiovascular system. Both the hypotensive response elicited by acute aerobic exercise and sleep quality can impact this dipping response. The purpose of this study was to investigate the effects of aerobic exercise timing on circadian BP changes and sleep architecture. Twenty prehypertensive subjects completed the study. During four test sessions, participants first completed a graded exercise test to exhaustion and then performed 30 minutes of treadmill exercise at 7 am (7A), 1 pm (1P), and 7 pm (7P) in a random, counterbalanced order at 65% of the heart rate obtained at peak oxygen uptake. An ambulatory cuff was used to monitor BP responses during 24 hours following exercise, and an ambulatory sleep-monitoring headband was worn during sleep following each session. Aerobic exercise at 7A invoked a greater dip in nocturnal systolic BP than exercise at 1P or 7P, although the greatest dip in nocturnal diastolic BP occurred following 7P. Compared to 1P, 7A also invoked greater time spent in deep sleep. These data indicate that early morning may be the most beneficial time to engage in aerobic exercise to enhance nocturnal BP changes and quality of sleep.
    Vascular Health and Risk Management 01/2014; 10:691-698. DOI:10.2147/VHRM.S73688

Full-text (2 Sources)

Download
12 Downloads
Available from
Sep 5, 2014